HCAR2 Antikörper (Middle Region)

Produktnummer ABIN952597

Produktdetails anti-HCAR2 Antikörper

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Bindungsspezifität: AA 207-236, Middle Region

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HCAR2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: This antibody recognizes Human GRP109A (Center). Other species not tested.

Aufreinigung: Protein A column, followed by peptide affinity purification

Immunogen: KLH conjugated synthetic peptide between 207-236 amino acids from the Central region of human GPR109A Genename: NIACR1

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu HCAR2

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Andere Bezeichnung: GPR109A (HCAR2 Produkte)

Synonyme: GPR109A antikoerper, HCA2 antikoerper, HM74a antikoerper, HM74b antikoerper, NIACR1 antikoerper, PUMAG antikoerper, Puma-g antikoerper, Gpr109a antikoerper, Gpr109b antikoerper, HM74 antikoerper, Hcar2 antikoerper, PUMA-G antikoerper, Pumag antikoerper, mHM74b antikoerper, HCAR2 antikoerper, HCAR3 antikoerper, hydroxycarboxylic acid receptor 2 antikoerper, HCAR2 antikoerper, Hcar2 antikoerper, LOC527744 antikoerper

Hintergrund: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamideSynonyms: G-protein coupled receptor 109A, G-protein coupled receptor HM74A, HM74A, NIACR1, Niacin receptor 1, Nicotinic acid receptor, PUMA-G, Pumag

Molekulargewicht: 41850 Da

Gen-ID: 338442

NCBI Accession: NP_808219